Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines

This article was originally published in The Pink Sheet Daily

Executive Summary

Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.


Related Content

FDA Advises Companies To Pay Close Attention to Raw Materials In Cell Therapy Manufacture
Deal Watch: Merck Digging Into Epigenetics With Proteros Partnership
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Patient Voices Swayed FDA's Imlygic Review Team
FDA 'Intercenter Institutes' Legislation Headed For Senate Mark-Up
FDA “Intercenter Institutes” Legislation Headed For Senate Mark-Up
New PD-1 Immunotherapy Combinations Push The Envelope In Melanoma
CHMP Nod Little Consolation As Amgen's Imlygic Becomes Melanoma Also-Ran
Yervoy Approval Has Shifted Development Landscape For Melanoma
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts